ArticleYonsei medical journal2026
Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study.
Article in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeRecent large-scale studies have investigated the risk of type 2 diabetes mellitus (T2DM) associated with the use of 5-alpha reductase inhibitors (5-ARIs) in benign prostatic hyperplasia (BPH) patients, but heterogeneous findings have been reported. This study aimed to examine the risk of T2DM associated with 5-ARIs (finasteride and dutasteride) compared to tamsulosin. MATERIALS AND
methodsWe identified nationwide cohorts of new users of finasteride, dutasteride, and tamsulosin without a history of prescriptions for 5-ARIs or tamsulosin within the previous 3 years among patients covered by national health insurance between 2010 to 2020 in South Korea. Patients were free of T2DM and had received at least 90 days of dispensation of the medications. We balanced cohorts on risk factors for T2DM based on age, health insurance status, index year, comorbidities, and co-medications using stabilized inverse probability of treatment weighting. Adjusted hazard ratios (HRs) were estimated using Cox proportional hazards models, with censoring for treatment discontinuation, switching, or augmentation, end of enrollment, and death.
resultsA total of 34874 tamsulosin users, 16953 finasteride users, and 19480 dutasteride users were included. The adjusted HR for finasteride was 1.06 [95% confidence interval (CI), 1.01-1.11] and that for dutasteride was 0.97 (95% CI, 0.92-1.02), when compared with tamsulosin users. These estimates were consistent in lag time analyses and attenuated among patients with good compliance.
conclusionThis study suggests minimal effects of finasteride and dutasteride on the risk of T2DM when compared with tamsulosin among patients with BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.